• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Kalderos names Brent Dover as new Chief Executive Officer

    2/3/22 7:00:00 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology
    Get the next $HCAT alert in real time by email

    CHICAGO, Feb. 3, 2022 /PRNewswire/ -- Health tech company Kalderos, which builds data-driven platform solutions for Drug Discount Management, is pleased to announce the appointment of Brent Dover as Chief Executive Officer. Dover succeeds former CEO Jeremy Docken, who co-founded Kalderos in 2016 and remains a member of the board. In his new role as Kalderos' Chief Strategy Officer, Docken will continue his focus on driving Kalderos' innovation of market-leading solutions.

    Brent Dover, Chief Executive Officer, Kalderos

    "We were impressed by Brent not only for his track record of creating value at growth stage companies like Kalderos, but also the way he connected personally with the vision and values that have motivated us from Kalderos' earliest days," said Docken. "I am eager for Kalderos' next chapter with Brent's experienced leadership." 

    Dover brings to Kalderos a wealth of leadership experience in emerging companies with a focus on data-driven healthcare solutions. Over the past two decades, Dover was instrumental in leading three such companies (Commure, Health Catalyst and Medicity) through rapid growth trajectories, joining each at the same pivotal stage Kalderos is at today.

    "We are thrilled to welcome Brent to Kalderos," said Yumin Choi, partner at Bain Capital Ventures and member of the Kalderos board of directors. "With Brent's expertise in healthcare information technology and his impressive credentials guiding growth stage companies to the next level, we are confident that he is the right leader for Kalderos at this exciting point in the company's history."

    Dover said, "Kalderos is using technology to solve challenges in a space where the tech infrastructure has been lacking. By connecting previously siloed data with a platform approach that builds trust between stakeholders, the company is uniquely positioned with a remarkable product-market fit. I am honored to have been invited to lead Kalderos through its next phase of rapid growth."

    Kalderos experienced accelerated growth in 2021, more than doubling its customer count and tripling sales. Along with the rapid expansion of new customers, Kalderos accelerated value delivery to existing customers and enjoyed its second year in a row of 100% customer retention. The company also deepened its focus on operations and commercialization, building teams and implementing processes to support even more rapid scaling in 2022. Recently, Built In named Kalderos one of "22 Chicago startups to watch in 2022."

    Dover most recently served as CEO at Commure (2019-2021), which in 2021 reached a $3.5 billion valuation. Previous to his role at Commure, Dover served as President of Health Catalyst (2013 - 2018), now a publicly traded healthcare analytics company (NASDAQ:HCAT). Before Health Catalyst, Dover served as President of Medicity (2007-2012), which sold to Aetna in 2011, generating a 16x return for investors.

    "Throughout my career, I've been dedicated to finding ways to use healthcare data to better support healthcare professionals and benefit the patients they serve," said Dover. "I look forward to continuing that journey with Kalderos, which is committed to using data transparency to ensure that drug discount programs can work as intended to help vulnerable patients and communities."

    In 2022, Kalderos will expand its portfolio of Drug Discount Management solutions with additional tools to support more stakeholder groups and provide enhanced end-to-end control and visibility of the Drug Discount Management workflow.

    About Kalderos

    Kalderos created the world's first Drug Discount Management platform, which uses sophisticated models and machine learning to resolve noncompliance issues in drug discount programs. The company's solutions include Discount Monitoring, which leverages a predictive model to identify and resolve historical instances of noncompliance, and 340B Pay, the first real-time solution for drug discount effectuation, which allows providers of any size to request 340B rebates and manufacturers to verify and pay them through a third party payment partner. Based in Chicago, Kalderos was founded in 2016 by a team dedicated to reducing inefficiencies in the U.S. healthcare system, empowering everyone to focus on the health of people. More information can be found at www.kalderos.com.

    Redefining how the business of healthcare performs.™ (PRNewsfoto/Kalderos)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kalderos-names-brent-dover-as-new-chief-executive-officer-301474355.html

    SOURCE Kalderos

    Get the next $HCAT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HCAT

    DatePrice TargetRatingAnalyst
    8/11/2025Buy → Neutral
    Citigroup
    8/8/2025$4.00Overweight → Neutral
    Cantor Fitzgerald
    6/17/2025Buy → Neutral
    BTIG Research
    4/9/2025Outperform → In-line
    Evercore ISI
    1/8/2025$9.00Sector Weight → Overweight
    KeyBanc Capital Markets
    4/10/2024Overweight → Sector Weight
    KeyBanc Capital Markets
    1/3/2024$14.00Overweight
    Barclays
    1/3/2024$11.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $HCAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Burton Daniel D. bought $204,525 worth of shares (26,200 units at $7.81), increasing direct ownership by 2% to 1,172,623 units (SEC Form 4)

    4 - Health Catalyst, Inc. (0001636422) (Issuer)

    2/27/24 4:01:39 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    $HCAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Health Catalyst Announces CEO Dan Burton to Step Down to Pursue Service Opportunities

    Mr. Burton to Retire June 30, 2026, Actively Committed to Support Board in Transition and New CEO Search SALT LAKE CITY, Aug. 7, 2025 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Health Catalyst Chief Executive Officer Dan Burton is stepping down from his role as CEO, effective June 2026, to enable additional time to pursue a few volunteer service opportunities he and his wife will participate in, in support of their faith, as active members of the Church of Jesus Christ of Latter-Day Saints.

    8/7/25 4:38:00 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Health Catalyst Reports Second Quarter 2025 Results

    SALT LAKE CITY, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (("Health Catalyst, NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2025. "For the second quarter of 2025, I am pleased by our strong financial results, including total revenue of $80.7 million and Adjusted EBITDA of $9.3 million, with these results beating our quarterly guidance on each metric." said Dan Burton, CEO of Health Catalyst. "I also want to share my plan to retire from the CEO role at Health Catalyst effective June 30, 2026. By then, I will have been leading Health Catalyst full-time

    8/7/25 4:03:00 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Health Catalyst to Announce Second Quarter 2025 Operating Results and Host Conference Call on Thursday, August 7, 2025

    SALT LAKE CITY, July 17, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst", , NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its second quarter 2025 operating results on Thursday, August 7, 2025, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day. Conference Call Details The conference call can be accessed by dialing 800-343-5172 for U.S. participants, or 203-518-9856 for international participants, and referencing conference ID "HCATQ225." A live audio webcast will be available online at https://ir.healthcatalyst.com/.

    7/17/25 8:30:00 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    $HCAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $HCAT
    SEC Filings

    View All

    Director Smith S. Dawn was granted 36,231 shares, increasing direct ownership by 55% to 101,692 units (SEC Form 4)

    4 - Health Catalyst, Inc. (0001636422) (Issuer)

    7/11/25 4:01:06 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Director Gallagher Duncan was granted 36,231 shares, increasing direct ownership by 47% to 113,282 units (SEC Form 4)

    4 - Health Catalyst, Inc. (0001636422) (Issuer)

    7/10/25 8:17:34 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Director Hoggard Green Jill was granted 36,231 shares, increasing direct ownership by 131% to 63,937 units (SEC Form 4)

    4 - Health Catalyst, Inc. (0001636422) (Issuer)

    7/10/25 8:17:24 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    SEC Form 10-Q filed by Health Catalyst Inc

    10-Q - Health Catalyst, Inc. (0001636422) (Filer)

    8/8/25 4:13:06 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Health Catalyst Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - Health Catalyst, Inc. (0001636422) (Filer)

    8/7/25 4:11:16 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Health Catalyst Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Health Catalyst, Inc. (0001636422) (Filer)

    7/10/25 5:26:18 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    $HCAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Health Catalyst downgraded by Citigroup

    Citigroup downgraded Health Catalyst from Buy to Neutral

    8/11/25 9:56:17 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Health Catalyst downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded Health Catalyst from Overweight to Neutral and set a new price target of $4.00

    8/8/25 8:19:52 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Health Catalyst downgraded by BTIG Research

    BTIG Research downgraded Health Catalyst from Buy to Neutral

    6/17/25 7:47:53 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    $HCAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Health Catalyst Inc

    SC 13G/A - Health Catalyst, Inc. (0001636422) (Subject)

    11/14/24 7:51:57 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    SEC Form SC 13G filed by Health Catalyst Inc

    SC 13G - Health Catalyst, Inc. (0001636422) (Subject)

    11/14/24 4:44:34 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by Health Catalyst Inc

    SC 13G/A - Health Catalyst, Inc. (0001636422) (Subject)

    11/12/24 3:55:05 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    $HCAT
    Financials

    Live finance-specific insights

    View All

    Health Catalyst Reports Second Quarter 2025 Results

    SALT LAKE CITY, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (("Health Catalyst, NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2025. "For the second quarter of 2025, I am pleased by our strong financial results, including total revenue of $80.7 million and Adjusted EBITDA of $9.3 million, with these results beating our quarterly guidance on each metric." said Dan Burton, CEO of Health Catalyst. "I also want to share my plan to retire from the CEO role at Health Catalyst effective June 30, 2026. By then, I will have been leading Health Catalyst full-time

    8/7/25 4:03:00 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Health Catalyst to Announce Second Quarter 2025 Operating Results and Host Conference Call on Thursday, August 7, 2025

    SALT LAKE CITY, July 17, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst", , NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its second quarter 2025 operating results on Thursday, August 7, 2025, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day. Conference Call Details The conference call can be accessed by dialing 800-343-5172 for U.S. participants, or 203-518-9856 for international participants, and referencing conference ID "HCATQ225." A live audio webcast will be available online at https://ir.healthcatalyst.com/.

    7/17/25 8:30:00 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Health Catalyst Reports First Quarter 2025 Results

    SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (("Health Catalyst, NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended March 31, 2025. "For the first quarter of 2025, I am pleased by our strong financial results, including total revenue of $79.4 million and Adjusted EBITDA of $6.3 million, with these results beating our quarterly guidance on each metric," said Dan Burton, CEO of Health Catalyst. "Additionally, we are happy to share that we added 10 net new Platform Clients in Q1 2025. This is especially encouraging given that Q1 is typically a quieter bo

    5/7/25 4:03:00 PM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    $HCAT
    Leadership Updates

    Live Leadership Updates

    View All

    Ardent Health Appoints Robert DeMichiei to Board of Directors

    Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Robert A. DeMichiei to its board of directors. A seasoned leader with over 30 years of experience in financial strategy, healthcare operations, and board governance, Mr. DeMichiei served as executive vice president and chief financial officer at the University of Pittsburgh Medical Center (UPMC) from 2004 to 2020. During his tenure, he played a pivotal role in driving UPMC's financial growth and led numerous strategic initiatives, including mergers and acquisitions, supply chain management, and revenue cycle improvements. Prior to joining U

    4/3/25 5:27:00 PM ET
    $AP
    $ARDT
    $HCAT
    Fluid Controls
    Industrials
    Hospital/Nursing Management
    Health Care

    Modern Health Welcomes Adam Brown as Chief Financial Officer

    Strengthens Executive Team with Seasoned Healthcare Finance Leader Modern Health, a leading global workplace mental health platform, today announces the appointment of Adam Brown as Chief Financial Officer. With an extensive background in healthcare finance and operations, including significant experience scaling high-growth healthcare technology companies, Brown brings deep industry expertise to the company. "Adam is a valued addition to Modern Health's leadership team, and we are thrilled to welcome him on board. His impressive track record and deep understanding of both public and private markets strengthens our executive bench as we continue to execute our vision," said Gyre Renwick

    1/15/25 10:16:00 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology

    Health Catalyst Signs Definitive Agreement to Acquire Upfront Healthcare Services

    SALT LAKE CITY, Jan. 13, 2025 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has signed a definitive agreement to acquire Upfront Healthcare Services, Inc. ("Upfront"), a next-generation patient engagement platform provider. Health Catalyst anticipates the acquisition will close in the first quarter of 2025.Upfront provides a market-leading patient activation and engagement platform and a proprietary strategic marketing analytics and content personalization solution for healthcare enterprises. Upfront's automated patient acquisition and retention solu

    1/13/25 8:00:00 AM ET
    $HCAT
    Computer Software: Programming Data Processing
    Technology